Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid

Active, not recruitingOBSERVATIONAL
Enrollment

122

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

September 20, 2024

Study Completion Date

December 20, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

in vitro (chemotherapy)

resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.

DEVICE

Adjuvant TACE(Adjuvant Transarterial Chemoembolization)

Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.

Trial Locations (1)

021

Eastern Hepatobiliary Surgery Hospital, Naval Medical University,, Shanghai

All Listed Sponsors
lead

Shen Feng

OTHER